Drug Information

Drug General Information
Drug ID
D09OOQ
Former ID
DIB013286
Drug Name
TGFK08AA-ER
Indication Generalized anxiety disorder [ICD9: 300, 300.02, 311; ICD10:F32, F40-F42, F41.1] Phase 2 [550644]
Company
Fabre Kramer Pharmaceuticals Inc
Target and Pathway
Target(s) 5-hydroxytryptamine 1A receptor Target Info Modulator [525395]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 550644Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
Ref 52539550 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. doi: 10.1038/nrd4075.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.